Posted inCardiology Internal Medicine news
Safety Profile Favors Apixaban Over Rivaroxaban in High-Risk Patients with Atrial Fibrillation and Peripheral Artery Disease
A large-scale cohort study reveals that while rivaroxaban and apixaban offer similar protection against limb events and stroke in patients with AF and PAD, rivaroxaban is associated with a 55% higher risk of major bleeding, suggesting apixaban as a safer alternative.
